Risk factors

AI adoption and cybersecurity receive new, detailed treatment, including model errors, privacy, vendor, recovery, and compliance risks.

The company added specific clinical, manufacturing, and regulatory risks regarding its cancer therapies. It also incorporated administrative drug pricing policy uncertainties.

Going concern doubts raised with $58.5M cash funding operations only into fourth quarter of 2026.

INTEST CORP added credit covenant waiver details, artificial intelligence integration risks, and international tariff exposures to its annual report.

Risk updates reflect streamlined disclosures regarding COVID-19, interest rate impacts on variable debt, and regional economic exposure in the southwestern United States.

Century Therapeutics experienced a workforce reduction, dropping full-time headcount from 150 to 78 employees. The company shifted its pipeline focus toward lead candidate CNTY-813 and CNTY-308. Net losses narrowed significantly to $9.6 million in 2025.

Opus Genetics faces severe share capital constraints with 69.9 million shares issued out of 125 million authorized. The company relies heavily on University of Pennsylvania and University of Florida patent licenses for its gene therapy pipeline. Regulatory oversight risks and Nasdaq minimum bid price compliance dominate the new operational disclosures.

KLX Energy Services added specific risks regarding debt leverage, cybersecurity and AI threats, climate change, and SEC baby-shelf limits. Debt balances decreased slightly, and equity share counts increased.

Liquidity and debt risks dominate, including cash generation, Term Loans, L/C collateral, and non-investment-grade ratings.

Market size and tariff changes added as new risks.

Korro Bio faces severe concentration risk on lead candidate KRRO-121 targeting hyperammonemia, with a planned IND filing in the second half of 2026.

Kingsway added operational risks covering Roundhouse, skilled labor, tariffs, and global conflicts while expanding acquisition debt figures.